Sebacia Postmarket Study of Real-World Use
| Status: | Recruiting |
|---|---|
| Conditions: | Acne, Acne, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 12 - 45 |
| Updated: | 1/30/2019 |
| Start Date: | January 1, 2019 |
| End Date: | June 2020 |
| Contact: | VP, Clinical & Regulatory Affairs |
| Email: | gretchen@sebacia.com |
| Phone: | 770-688-1280 |
A Prospective, Multicenter, Postmarket Study of Sebacia Microparticles Treatment in Patients Using Topical Acne Products for Mild to Moderate Inflammatory Acne Vulgaris
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for
patients with mild to moderate inflammatory acne vulgaris.
patients with mild to moderate inflammatory acne vulgaris.
Inclusion Criteria:
- Mild to moderate facial inflammatory acne vulgaris (IGA 2 or 3)
- Between 10 and 50 papules/pustules
- Fitzpatrick skin phototype I, II or III
- Able to provide informed consent and comply with study schedule and other requirements
Exclusion Criteria:
- Moderately severe or severe acne vulgaris (IGA 4 or 5)
- Nodulocystic acne, significant scarring or excoriation
- Requires oral retinoid, antibiotic or corticosteroid for acne
- New or fluctuating hormone or hormone-regulating therapy
- Photosensitivity or allergy to gold
- Medical or mental health condition that would pose a risk to patient or impair
treatment and evaluation
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials